{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:54:46Z","timestamp":1792212886386,"version":"4.4.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This work is supported by the American University of Beirut, CNRS-C\u00e8dre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the"},{"name":"This work is supported by the American University of Beirut, CNRS-C\u00e8dre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006854","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T13:54:00Z","timestamp":1542808440000},"page":"e0006854","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9125-5137","authenticated-orcid":true,"given":"Rana","family":"El Hajj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanady","family":"Bou Youness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lachaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Masquefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antoine","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-0477","authenticated-orcid":true,"given":"Hiba","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khalifeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,21]]},"reference":[{"issue":"23","key":"ref1","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1021\/jm9004835","article-title":"Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania","volume":"52","author":"A Cavalli","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"e0005739","DOI":"10.1371\/journal.pntd.0005739","article-title":"A new perspective on cutaneous leishmaniasis\u2014Implications for global prevalence and burden of disease estimates","volume":"11","author":"F Bailey","year":"2017","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/bmb\/ldl003","article-title":"Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment","volume":"75","author":"MT Roberts","year":"2005","journal-title":"British Medical Bulletin"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3201\/eid2205.160042","article-title":"Cutaneous leishmaniasis and conflict in Syria","volume":"22","author":"WS Al-Salem","year":"2016","journal-title":"Emerging Infectious Diseases"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3201\/eid2010.140288","article-title":"Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees, Lebanon","volume":"20","author":"M Saroufim","year":"2014","journal-title":"Emerging Infectious Diseases"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apjtm.2016.06.021","article-title":"Worldwide risk factors in leishmaniasis","volume":"9","author":"A Oryan","year":"2016","journal-title":"Asian Pacific Journal of Tropical Medicine"},{"issue":"issue","key":"ref7","first-page":"CD005067","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"4","author":"U Gonz\u00e1lez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-4362.2002.01526.x","article-title":"Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis","volume":"41","author":"I Esfandiarpour","year":"2002","journal-title":"International Journal of Dermatology"},{"issue":"22","key":"ref9","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.2217\/fon.15.192","article-title":"Topical treatment of basal cell carcinoma with the immune response modifier imiquimod","volume":"11","author":"D Papakostas","year":"2015","journal-title":"Future Oncology"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites","volume":"3","author":"R Hadighi","year":"2006","journal-title":"PLoS Medicine"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bmc.2003.11.034","article-title":"Design and synthesis of novel imidazo [1, 2-a] quinoxalines as PDE4 inhibitors","volume":"12","author":"C Deleuze-Masqu\u00e9fa","year":"2004","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"I Arevalo","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"C Miranda-Verastegui","year":"2009","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fimmu.2012.00144","article-title":"Adjuvants for Leishmania vaccines: from models to clinical application","volume":"3","author":"VS Raman","year":"2012","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1086\/324161","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator","volume":"33","author":"I Arevalo","year":"2001","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","article-title":"Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial","volume":"142","author":"A Firooz","year":"2006","journal-title":"Archives of Dermatology"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bmc.2016.04.004","article-title":"New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure\u2013activity relationships","volume":"24","author":"Z Zghaib","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/cncr.30515","article-title":"Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia","volume":"123","author":"AI Nabbouh","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/CAD.0000000000000084","article-title":"EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells","volume":"25","author":"J Saliba","year":"2014","journal-title":"Anti-cancer Drugs"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1128\/IAI.01527-07","article-title":"Immunization with a Toll-like receptor 7 and\/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB\/c mice","volume":"76","author":"WW Zhang","year":"2008","journal-title":"Infection and Immunity"},{"issue":"5625","key":"ref21","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1085536","article-title":"Toll-like receptor signaling pathways","volume":"300","author":"GM Barton","year":"2003","journal-title":"Science"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2010.177","article-title":"Non-canonical NF-\u03baB signaling pathway","volume":"21","author":"SC Sun","year":"2011","journal-title":"Cell Research"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/jcmm.12718","article-title":"Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-\u03baB inhibition","volume":"20","author":"A El-Khattouti","year":"2016","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/20477724.2016.1232042","article-title":"Pro-and anti-inflammatory cytokines in cutaneous leishmaniasis: a review","volume":"110","author":"N Maspi","year":"2016","journal-title":"Pathogens and Global Health"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.lfs.2003.10.042","article-title":"iNOS-mediated nitric oxide production and its regulation","volume":"75","author":"F Aktan","year":"2004","journal-title":"Life Sciences"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1084\/jem.180.3.783","article-title":"Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major","volume":"180","author":"S Stenger","year":"1994","journal-title":"Journal of Experimental Medicine"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"D Sacks","year":"2002","journal-title":"Nature Reviews Immunology"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"I Arevalo","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1128\/IAI.71.10.5739-5749.2003","article-title":"gp63 homologues in Trypanosoma cruzi: surface antigens with metalloprotease activity and a possible role in host cell infection","volume":"71","author":"IC Cuevas","year":"2003","journal-title":"Infection and Immunity"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3201\/eid0906.030026","article-title":"Anthroponotic cutaneous leishmaniasis, Kabul, Afghanistan","volume":"9","author":"R Reithinger","year":"2003","journal-title":"Emerging Infectious Diseases"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"e3208","DOI":"10.1371\/journal.pntd.0003208","article-title":"Leishmaniasis in the Middle East: incidence and epidemiology","volume":"8","author":"N Salam","year":"2014","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1469-0691.2011.03630.x","article-title":"Leishmaniasis chemotherapy\u2014challenges and opportunities","volume":"17","author":"SL Croft","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.exppara.2006.12.004","article-title":"Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod","volume":"116","author":"J El-On","year":"2007","journal-title":"Experimental Parasitology"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/314782","article-title":"Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action","volume":"179","author":"S Buates","year":"1999","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0192-0561(98)00068-X","article-title":"Review article imiquimod applied topically: a novel immune response modifier and new class of drug","volume":"21","author":"RL Miller","year":"1999","journal-title":"International Journal of Immunopharmacology"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1084\/jem.187.1.129","article-title":"Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s","volume":"187","author":"R Bonecchi","year":"1998","journal-title":"Journal of Experimental Medicine"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0167-5699(98)01346-2","article-title":"Chemokines and chemokine receptors in T-cell priming and Th1\/Th2-mediated responses","volume":"19","author":"F Sallusto","year":"1998","journal-title":"Immunology Today"},{"issue":"4","key":"ref38","first-page":"570","article-title":"Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis","volume":"69","author":"FY Liew","year":"1990","journal-title":"Immunology"},{"issue":"12","key":"ref39","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.humimm.2010.09.002","article-title":"Chemokines and chemokine receptors coordinate the inflammatory immune response in human cutaneous leishmaniasis","volume":"71","author":"AP Campanelli","year":"2010","journal-title":"Human Immunology"},{"key":"ref40","first-page":"1","article-title":"Nitric oxide production by Leishmania-infected macrophages and modulation by cytokines and prostaglandins","volume":"43","author":"O Brandonisio","year":"2001","journal-title":"Parassitologia"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/jlb.50.1.93","article-title":"Cytokine-Induced Synthesis of Nitrogen Oxides in Macrophages: A Protective Host Response to Leishmania and Other Intracellular Pathogens","volume":"50","author":"SJ Green","year":"1991","journal-title":"Journal of Leukocyte Biology"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s005990050076","article-title":"Inducible nitric oxide synthase and nitric oxide production in Leishmania infantum-infected human macrophages stimulated with interferon-\u03b3 and bacterial lipopolysaccharide","volume":"29","author":"MA Panaro","year":"1999","journal-title":"International Journal of Clinical and Laboratory Research"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2230.2005.01758.x","article-title":"Serum antioxidant activities, malondialdehyde and nitric oxide levels in human cutaneous leishmaniasis","volume":"30","author":"G Serarslan","year":"2005","journal-title":"Clinical and Experimental Dermatology"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/eji.200324128","article-title":"MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling","volume":"33","author":"MJ de Veer","year":"2003","journal-title":"European Journal of Immunology"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.182.3.1386","article-title":"TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions","volume":"182","author":"FH Fakher","year":"2009","journal-title":"The Journal of Immunology"},{"issue":"1\u20133","key":"ref46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejps.2009.10.006","article-title":"Pharmacology of EAPB0203, a novel imidazo [1, 2-a] quinoxaline derivative with anti-tumoral activity on melanoma","volume":"39","author":"S Khier","year":"2010","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C T method","volume":"3","author":"TD Schmittgen","year":"2008","journal-title":"Nature Protocols"},{"issue":"41","key":"ref48","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.3748\/wjg.v19.i41.7121","article-title":"Reference genes for quantitative RT-PCR data in gastric tissues and cell lines","volume":"19","author":"F Wisnieski","year":"2013","journal-title":"World Journal of Gastroenterology: WJG"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0560.2011.01861.x","article-title":"Molecular diagnosis of cutaneous leishmaniasis and species identification: analysis of 122 biopsies with varied parasite index","volume":"39","author":"L Yehia","year":"2012","journal-title":"Journal of Cutaneous Pathology"},{"key":"ref50","article-title":"Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis","author":"AA Grosset","year":"2017","journal-title":"Applied Immunohistochemistry and Molecular Morphology"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T13:39:32Z","timestamp":1662471572000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006854"}},"subtitle":[],"editor":[{"given":"Sima","family":"Rafati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,21]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006854","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734477981.793580950","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,21]]}}}